Emeryville, United States
Slingshot Biosciences, founded in 2012 and headquartered in the United States, is a pioneering entity in the Biotechnology and Health and Wellness sectors with their slogan, “Next-Generation Synthetic Cells”.
The company addresses a critical gap in healthcare: the inconsistency of reference materials for cell-based assays, which significantly impact patient outcomes. By developing synthetic cell mimics, Slingshot Biosciences provides a novel solution for creating precise, biologically-relevant controls that serve a multitude of applications—from assay setup and validation to quality control in manufacturing. This innovation promises a scalable, cost-effective approach to global healthcare and research challenges.
Their most recent financial milestone was securing a $26.23M Series A investment on 06 February 2023, supported by investors including Arch Venture Partners, Anterra Capital, and Northpond Ventures. This investment underscores the confidence and potential seen by industry leaders in Slingshot Biosciences to transform the landscape of cell-based testing solutions.
Ovizio
